Navigation Links
Nektar Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/2/2011

formation and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share information)(Unaudited)Three Months EndedNine Months EndedSeptember 30, September 30,2011201020112010Revenue:Product sales and royalties

$  10,222$  7,230$  26,023$  21,968License, collaboration and other

16,84630,69529,67591,757Total revenue

27,06837,92555,698113,725Operating costs and expenses:Cost of goods sold

5,0386,24516,44115,430Research and development

31,01827,72493,46476,610General and administrative

12,35010,18135,26229,401Total operating costs and expenses

48,40644,150145,167121,441Loss from operations

(21,338)(6,225)(89,469)(7,716)Non-operating income (expense):Interest income

6223691,5831,225Interest expense

(2,543)(2,826)(7,698)(8,686)Other income (expense), net

(717)249(599)436Total non-operating expense

(2,638)(2,208)(6,714)(7,025)Loss before provision for income taxes

(23,976)(8,433)(96,183)(14,741)Provision for income taxes

92278300617Net loss

$ (24,068)$ (8,711)$ (96,483)$ (15,358)Basic and diluted net loss per share

$
(0.21)$   (0.09)$
(0.86)$
(0.16)Weighted average shares outstanding used in computing basic and diluted net loss per share

114,41394,213112,43593,972NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)Nine Months Ended September 30,20112010Cash flows from operating activities:Net loss

$   (96,483)$ (15,358)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

11,42412,499Stock-based compensation

14,50112,716Other non-cash transactions

967(176)Changes in operating assets and liabilities:Accounts receivable

12,188(752)Inventory'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
(Date:7/30/2015)... 30, 2015  ResMed Inc. (NYSE: RMD ) ... 2015.  Revenue for the quarter was $453.1 million, a ... 30, 2014 (a 17 percent increase on a constant ... the quarter ended June 30, 2014.  Diluted earnings per ... quarter ended June 30, 2014.  The ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... Stereotaxis, Inc. (Nasdaq: STXS ) today ... the Company its 100th patent, a major intellectual property ... the "Method and Apparatus for Dynamic Magnetic Field Control ... commitment to innovate and protect its leading position in ...
... Calif., Sept. 20 Questcor Pharmaceuticals, Inc. (Nasdaq: ... UBS Global Life Sciences Conference on Wednesday, September 22, 2010 ... Bailey, President and Chief Executive Officer, will discuss the Company,s ... Time. Attendance at this conference is by invitation ...
Cached Medicine Technology:Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent 2Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent 3Stereotaxis Achieves Intellectual Property Milestone With 100th U.S. Patent 4
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Girl Scouts ... out bullying across Georgia through the Girl Scout "Be a Friend First" program. Representatives ... Thursday, July 30. , “Peach State Health Plan and our parent company, Centene ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The Mount ... on research projects that evaluate the potential of related, experimental treatments. The collaboration moves ... of Health to award Columbia Care one of five state licenses to produce and ...
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic ... aging diseases. , BioViva announces it has begun a fundraiser through Maximum Life ... (AD) and find a cure. MaxLife will grant 100% of the money raised to ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the ... the women experienced spontaneous migration of their Implanon® implants, inability to locate the ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a patient's ... heart rate of 150 beats versus 100 beats, this is a big deal," says ... give life back to patients with heart disease," he adds. People with angina are ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... measures, study finds , FRIDAY, Aug. 7 (HealthDay News) -- ... cancer have surgery to remove their breasts or ovaries in ... report. , Their study included 211 women, aged 35 to ... to increase the risk of breast and ovarian cancer. The ...
... , , WEST JORDAN, Utah, Aug. ... Jewish Community Center (JCC) the fourth annual Dannon Next Generation Nutrition Grant ... Lake County community. The JCC received $30,000 in support of its ... Fun, Fit & Healthy! will offer weekly, nutritionist-developed ...
... /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: ... Chairman and Chief Executive Officer, will present at the upcoming ... will take place on Wednesday, August 12, 2009 at 11:00 ... About Transition, ----------------, , ...
... , , , , ... selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for ... wrinkles. Kathleen Stegman, RN, M.A. has been an avid Artefill user ... for the long lasting correction of wrinkles. , , ...
... LAUDERDALE, Fla., Aug. 7 Averaging ... critical 24/7 patient information call center, Hospice Partners On Call ... secure colocation facility, to safeguard its powerful server infrastructure and ... Partners On Call decided to move their back-up servers to ...
... , DENVER, Aug. 7 An innovative program ... disease patients and teams of pharmacists, nurses, primary care doctors, and ... two years after they left the program by keeping them in ... by Kaiser Permanente published in The American Journal of Managed Care ...
Cached Medicine News:Health News:Many Opt for Surgery to Lower Breast, Ovarian Cancer Risk 2Health News:The Dannon Company Awards The I.J. & Jeanne Wagner Jewish Community Center the Fourth Annual Dannon Next Generation Nutrition Grant 2Health News:The Dannon Company Awards The I.J. & Jeanne Wagner Jewish Community Center the Fourth Annual Dannon Next Generation Nutrition Grant 3Health News:The Dannon Company Awards The I.J. & Jeanne Wagner Jewish Community Center the Fourth Annual Dannon Next Generation Nutrition Grant 4Health News:Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference 2Health News:Midwest Medical Aesthetics Helps Defy Nature and Wrinkles with Artefill 2Health News:Midwest Medical Aesthetics Helps Defy Nature and Wrinkles with Artefill 3Health News:Hospice Partners On Call Selects Category 5 Hurricane Rated 1Vault Networks to Safeguard Server and Call Center Infrastructure 2Health News:Electronic Health Records Help Cardiac Patients Remain Healthy 2Health News:Electronic Health Records Help Cardiac Patients Remain Healthy 3Health News:Electronic Health Records Help Cardiac Patients Remain Healthy 4
... Tamtron PowerPath is IMPACs comprehensive ... anatomic pathology laboratories to integrate and ... needs through a single, intuitive software ... more than 350 institutions have proven ...
The most compact revolutionary innovation in hematology. 8 or 18 automated parameter hematology analyzer....
... vision controls all refractor operations ... from the wireless remote control. ... can be loaded into the ... transfer. The illuminated LED heads-up ...
... in clinical color vision tests. It is ... or blue/yellow color vision losses that accompany ... Plaquenil, for example), early optic neuritis, glaucoma, ... is fast and accurate in quantifying congenital ...
Medicine Products: